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Abstract Glomerular thrombotic microangiopathy is a
hallmark feature of haemolytic uraemic syndrome, the
leading cause of acute renal failure in childhood. This
paper is a review of the different mechanistic pathways that
lead to this histological picture in the kidney. It will focus
on atypical HUS and complement dysregulation, but will
also highlight some other recent advances in our under-
standing of this condition, including the potential role of the
molecule vascular endothelial growth factor- A (VEGF-A).
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Introduction
Haemolytic uraemic syndrome (HUS) is the most common
cause of paediatric acute renal failure affecting between 0.2
and 4.28 people per 100,000 worldwide [1]. It is categor-
ised as a thrombotic microangiopathy (TMA). TMA is a
pathological term used to describe occlusive microvascular
thrombus formation [2], which was first described in 1952
by Symmers (cited in Ruggenenti et al. [3]). Pathological
features include vessel wall thickening, swelling and
detachment of the endothelial cell from the basement
membrane, accumulation of material in the subendothelial
space, intraluminal platelet thrombosis, partial or complete
vessel luminal obstruction and fragmentation of red blood
cells (Fig. 1)[ 3–6].
Clinically, TMA is associated with consumptive throm-
bocytopaenia, microangiopathic haemolytic anaemia and
features of organ ischaemia [5]. The symptoms produced
depend on the vascular bed and organ affected. TMA is
most commonly associated with HUS and thrombotic
thrombocytopaenic purpura (TTP) [2]. In TTP neurological
endothelial cells are predominantly affected and so clinically
neurological features are seen [5]. In HUS the TMA is
predominantly seen in the glomeruli and thus results in acute
renal insufficiency [5]. TTP and HUS are often considered
together because of their similar aetiology and the fact that
clinically there can be symptom overlap with neurological
features seen in HUS and renal problems seen in TTP.
Atypical HUS is more commonly associated with extra-renal
effects than typical HUS [3]. Also, HUS is more commonly
seen in children and TTP in adults [7]. The underlying
reasons for this are unclear at present. TMA has many
associations and precipitating factors (Fig. 2)[ 4, 8, 9].
Haemolytic uraemic syndrome has a variety of precip-
itating factors that help to categorise it into the traditional
descriptions of typical and atypical [2]. It is more common
in children under 5 years with an incidence of 6.1 cases per
100,000 per year [10]. The most common version of HUS
is the ‘typical’ variety or diarrhoea-associated HUS (D +
HUS). This has recently been termed infection-associated
HUS [11]. Ninety percent of HUS cases are associated with
infection [12]. Typically, this results from E. coli O157
infection, which produces Shiga toxin and causes a
preceding diarrheal illness, but Streptococcus pneumoniae
infection can also cause HUS (no diarrhoea). The variation
in incidence is thought to reflect the differences in D +
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there are higher rates of both E. coli O157 infection and
D + HUS in Scotland compared with the rest of the country
[13]. This may reflect a more rural population with more
private water supplies. Only 10–15% of children who get E.
coli O157 go on to develop HUS [10]. It is unclear why
some children develop glomerular TMA and others do not.
A genetic predisposition is possible, but as yet undefined.
Ten percent of cases of HUS fall into the “atypical”
category. European prevalence is estimated to be 7 per
million children [11]. Atypical cases have a variety of
associated features and triggers, but include familial cases,
which are now understood to be disorders of complement
activation as a result of loss of normal regulatory factors or
by activating mutations [9]. Other factors that can produce
atypical HUS include pregnancy, drugs, malignancy, con-
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Fig. 1 Thrombotic microangi-
opathy: “the final events”.
Thrombotic microangiopathy is
the pathological process that is
the final common pathway of
many disease processes, but is
most commonly associated with
haemolytic uraemic syndrom
(HUS) and thrombotic
thrombocytopaenic purpura
(TTP). Pathological features
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thickness, swelling and/or
detachment of endothelial cells,
platelet aggregation/thrombosis,
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in subendothelial space and
partial or complete vessel
occlusion. Clinically:
microangiopathic haemolytic
anaemia—sheer stress from
vessel lumen occlusion
produces fragmented red cells,
thrombocytopaenia—platelets
are consumed by local throm-
bosis and organ ischaemia—
renal failure or neurological
symptoms
TMA
Infection induced:
-Shigatoxin HUS
-Strep Pneumoniae HUS
Disorders of Complement regulation
-Genetic mutations
-Acquired defects e.g. antibodies
ADAMTS 13 abnormalities:
-genetic abnormality
-Autoantibodies
Drugs:
-Quinine induced
-Tacrolimus, ciclosporin
-Bleomycin, mitomycin,
cisplatin
-rifampicin
-Clopidopogrel
Defective cobalamin
metabolism
Pregnancy
HIV
Malignancy Connective tissue
disorders:
-SLE
-Antiphospholipids
syndrome
Fig. 2 Precipitants of thrombotic
microangiopathy (TMA). SLE
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524 Pediatr Nephrol (2011) 26:523–533nective tissue disorders and metabolic defects [9]. Atypical
HUS can present with an infective trigger and these cases
can be difficult to distinguish from typical cases in the early
stages of illness. Atypical forms of HUS are rare, but carry
a poorer prognosis with significant morbidity and mortality
[11]. There has been improved understanding of glomerular
TMA and HUS in the past few years; however, there are
still many questions yet to be answered.
Atypical haemolytic uraemic syndrome
Atypical haemolytic uraemic syndrome (HUS) is an
uncommon condition that is now widely accepted to be a
disorder of complement over activation. It carries a poorer
prognosis than infection-associated HUS with a 25%
mortality rate and 50% developing end-stage renal failure
[11]. Most of the familial mutations described result in loss
of regulation of the complement cascade; however, some
activating mutations have also been described, e.g. C3 [14]
and factor B [15]. It is members of the alternative
complement pathway that are affected, either as a result of
genetic mutations or by the presence of antibodies against
members of the complement regulatory system [9]. This
includes complement factors H and I and membrane co-
factor protein (MCP), which are found to be mutated in
50% of atypical HUS patients [2, 5]. These molecules
prevent inappropriate complement activation against “self-
cells” in the body. Thus, mutations and antibodies that alter
their function result in overwhelming complement activa-
tion directed at self cells, i.e. glomerular endothelial cells. It
has been hypothesised that certain vascular beds are more at
risk from this process. The glomerulus is thought to be a
target because it is fenestrated and so the subendothelial
matrix is continually exposed to circulating proteins [16].
Atypical HUS is commonly recurrent and carries a poor
prognosis with significant mortality and can lead quickly to
end-stage renal failure. It was first described by Gasser in
1955 (cited in Ruggenenti et al. [3]).
In 1974, it was identified that atypical HUS patients had
low C3 levels and normal C4 levels reflecting complement
activation and consumption. This was the first link between
HUS and complement [16].
Normal complement cascade
To understand the pathogenesis of atypical HUS we must
first understand the normal complement pathway. The
complement system is a group of 30 proteins that are part
of the innate immune system that protects against invading
organisms [16]. They “complement” the antibacterial
properties of antibodies. These proteins can be plasma-
based (fluid) or membrane-bound (solid) and have either
activation or regulatory functions. There are three main
branches of the complement pathway: classical, lectin and
alternative. The classical pathway is activated by antigen-
antibody binding whilst the lectin pathway is activated by
serum lectin binding to mannose-containing carbohydrates
on bacteria and viruses. The alternative pathway is
triggered by complement proteins binding to the surface
of pathogens [17]. The end result of each pathway is the
production of proteases complexes (C3 convertases and C5
convertases) that cleave C3 and C5, which leads to the
activation of the membrane attack complex (MAC), creating
pores in membranes. It is the alternative complement
pathway that is affected in atypical HUS. This pathway
provides an amplification loop that can be triggered alone or
complement to the classical pathway. This cascade starts
with C3 hydrolysis in plasma and results in C3b deposition
onto almost all exposed cell surfaces (see Fig. 3).
Complement activation is regulated by plasma and
membrane-bound regulators that act to cleave C3b to
inactive C3b (C3bi; Fig. 4)[ 16]. Complement factors H
and I are crucial for this process. Without this regulation,
C3b deposition increases exponentially causing activation
of the complement cascade. This continues until compo-
nents are consumed. If cells do not have membrane-bound
regulators or cannot bind soluble receptors, they are
attacked by complement. C3b deposits on bacterial cells
act as a tags and bind to neutrophil receptors, causing
phagocytosis.
Serum-based complement factors
This review will focus on the two factors that have been
most intensely studied, factors H and I.
Complement factor H
Complement factor H is a serum glycoprotein synthesised in
the liver and a regulatory member of the alternative
complement pathway [18]. Mutations in the gene were first
described in 1998 [19]. Further studies went on to show that
reduced complement factor H levels can be found in patients
with atypical HUS, but also in their asymptomatic family
members. Most mutations are inherited in an autosomal
dominant fashion with variable penetrance. Furthermore,
normal levels of complement factor H do not rule out
functional problems. There have been reports of antibodies
directed against this factor, which reduces its functional
capacity [20]. Factor H mutations can be seen from the
neonatal period to adulthood. Antibodies against factor H are
seen predominantly in the pre-adolescent period. Mutations
account for 6–11% of cases of atypical HUS [20]. The factor
Pediatr Nephrol (2011) 26:523–533 525H gene is found on 1q32 where many other complement
regulatory genes are also found [19, 21, 22].
Factor H is a fluid phase complement regulator [20]. It
inhibits the formation of the alternative C3-convertase and
accelerates its decay (see Fig. 4). The complement
regulatory section of factor H is found in its N-terminal
whilst the C-terminal harbours the membrane-binding
section [20, 23, 24]. Sixty to eighty percent of aHUS
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Fig. 4 Complement regulators
are shown circled in red. These
include factors H and I and
membrane co-factor protein. Each
acts to promote the inactivation of
C3b and prevent further progres-
sion of the complement cascade.
Factor H binds Cb3 and works
with factor I to inactivate it. Both
complement factors H and I are
serum-based. Membrane co-factor
protein is cell-bound. It also binds
to C3b, which has become
attached to cells and works with
factor I to inactivate it. Thrombo-
modulin is also shown as muta-
tions and has been associated with
atypical HUS. It regulates com-
plement by acting to inactivate the
proinflammatory mediators C3a
and C5a and accelerating factor
I-mediated C3b inactivation. It
also plays a role in local coagu-
lation regulation through its inter-
actions with thrombin
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Fig. 3 The alternative pathway is triggered by the covalent binding of
C3b to a pathogen or cell surface. Next, factor B binds to surface bond
C3b, making it susceptible to plasma factor D cleavage. The result is
production of Ba and active protease Bb, which remains bound to C3b
creating C3bBb, which is the C3 convertase of the alternative
complement pathway. This starts the amplification loop with C3
convertase generating more C3b on the cell surface and the process
repeats. Ultimately, there will be C3b saturation on the cell surface
with release of C3a, a small inflammatory mediator. Eventually, some
of the C3b binds to pre-existing C3 convertase producing C3b2Bb,
which is the alternative pathway’s C5 convertase. This cleaves C5 into
C5b, which generates the membrane attack complex (MAC), and C5a,
a potent pro-inflammatory mediator. Complement-mediated endothe-
lial cell injury creates a prothrombotic state. It exposes subendothelial
collagens and releases von Willebrand factor and fibrinogen formation
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terminal binds to glycosaminoglycans on endothelial cells
and basement membrane [24]. Factor H binds to cell
surface-bound C3b (Fig. 4). Factor H is a serum-based
factor that can bind to self cells and protects them from
being attacked by the complement system. It is thought that
dysfunction or reduced levels of factor H causes problems
with cell recognition during an inflammatory insult [16].
The result is endothelial cell damage causing exposure of
the subendothelial matrix. The result is a full complement
attack and thrombus formation. This will produce platelet
consumption and red cell damage. Thus, TMA is produced
(Fig. 5)[ 25]. Interestingly, there is now also good evidence
that factor H is also produced by platelets and can modify
their function [26, 27].
Linkage studies helped identify mutations in factor H in
cases of atypical HUS [19]. Naturally, attention then turned
to the creation of mouse models to better understand the
pathogenesis and cellular interactions. Interestingly, the
factor H null mouse [28] does not get HUS, but develops
severe membranoproliferative glomerulonephritis (MPGN),
which can also occur in humans with factor H mutations.
This mouse developed uncontrolled alternative complement
pathway activation and has very low C3 levels. A similar
scenario occurred in a pig model [29]. Other models have
been developed, in particular a mouse that lacks the C-
terminal function of factor H [30]. This mouse had higher
C3 levels and did develop HUS. This proved that factor H
mutations cause HUS by impairing cell surface recognition,
resulting in local complement dysregulation. It was only the
homozygous mice that developed HUS, in contrast to
humans, where one defective allele is enough to predispose
to HUS.
Complement factor I
Factor I is another serum-based member (fluid component)
of the complement regulation system. It is also predomi-
nantly produced in the liver. It is a serine protease that
cleaves C3b and thus plays a key inhibitory role in
preventing alternative pathway amplification (prevents
formation of C3 convertase [C3bBb] from C3b; Fig. 4)
[16]. The function of factor I depends on many co-factors,
including factor H and C4-binding protein. There are also
membrane-bound molecules, which also play a role in C3b
cleavage. These include CD35 and membrane co-factor
protein (CD46) [31].
Factor I mutations causing HUS were first described in
2004 [31]. The factor I gene is found on chromosome 4.
Mutations were found in sporadic cases rather than familial,
suggesting a low penetrance of mutations. The abnormal
gene encodes truncated factor I protein, which lacks the C-
terminal including the serine proteinase region. The serine
proteinases are a large group of biologically important
enzymes that includes trypsin, other complement proteins,
C2, C1r, C1s, factor D, and factor B, and proteins of the
fibrinolytic and coagulation cascades. Factor I contains the
catalytic triad of amino acids aspartic acid, histidine and
serine, a triad common to all serine proteinases.
In factor I deficiency, the alternative pathway is not
regulated (Fig. 5) and in a similar way to factor H deficiency,
the final result is TMA. This leads to a consumptive
depletion of C3 and factor B. Complete hereditary deficiency
of factor I has been reported in at least 30 different pedigrees
and is associated with severe pyogenic infections [31].
Patients with mutations or antibodies against these
serum-based complement regulators have a poorer progno-
sis especially with regard to transplantation. They have
been shown to develop recurrence in their grafts and so
transplantation cannot be recommended in this group for
this reason at present [11]. However, as complement factors
H and I are synthesised by the liver, either an isolated liver
transplant or a combined liver and kidney transplant can be
considered, but only in centres with previous experience of
these cases [11]. Factor I knockout mice show uncontrolled
alternative pathway activation, but, similar to factor H
knockouts, do not develop HUS, instead they develop
mesangial C3 deposits [29].
Membrane-bound complement factors
Membrane co-factor protein (MCP or CD46)
Membrane co-factor protein is a widely expressed trans-
membrane complement regulator. It is expressed on almost
every cell except erythrocytes. It works with factor I to
degrade C3b and C4b, which are bound to the host cell
surface (see Fig. 4). The MCP gene is also found on
chromosome 1q32 [21].
Membrane co-factor protein mutations cause the protein
to be incorrectly processed and so remains intracellular or
affects C3b binding. Both autosomal dominant inheritance
with variable penetrance and autosomal recessive patterns
have been seen. In some pedigrees subjects carry mutations,
but do not develop HUS suggesting that the mutation alone
is not always enough to develop the disease. There does
seem to be an endothelial insult that triggers the initiation of
HUS. It is after this that overwhelming complement
activation results and TMA develops (Fig. 5). As MCP is
membrane-bound and not serum-bound, renal transplanta-
tion is successful in this patient group [21].
There is no way of developing a good mouse model to
investigate this membrane-bound protein because of inher-
ent differences between human and mouse complement
systems. Mice lack MCP expression in their glomeruli; it is
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complement regulatory protein (crry), which has co-factor
activity and decay-accelerating factor activity. Crry knock-
out is embryologically lethal. A mouse that has crry
knockout and C5 knockout does exist. Kidneys from this
mouse have been transplanted into mice with fully
functioning complement. These kidneys fail due to uncon-
trolled complement activation.
Thrombomodulin
Recently, it has been discovered that mutations in throm-
bomodulin can trigger atypical HUS. Thrombomodulin is a
ubiquitous transmembrane endothelial cell glycoprotein
with anticoagulant, anti-inflammatory and cytoprotective
properties [32]. It is anchored to the cell by a short
cytoplasmic tail and single transmembrane domain. In vitro
it binds C3b and complement factor H. It negatively
regulates complement by accelerating factor I-mediated
inactivation ofC3binthe presenceofco-factors(factorHand
C4b binding protein). It also promotes activation of plasma
procarboxypeptidase B (or thrombin activatable fibrinolysis
inhibitor = TAFI) and accelerates inactivation of anaphylatox-
ins C3a and C5a (Fig. 4). It also accelerates thrombin-
mediated activation of protein C, which down-regulates
further thrombin generation and suppresses clot formation.
Thrombomodulin interferes with inflammation by sup-
pressing leukocyte trafficking and dampening complement
activation via its lectin-like domain. Mutations in this
domain alter factor H and C3b binding and thus comple-
ment regulation. Mutations in the serine–threonine-rich
region alter factor I-mediated Cb3 inactivation. Interesting-
ly, in the landmark paper by Delvaeye et al. [32], one
patient had recurrence of atypical HUS post-renal trans-
plantation despite thrombomodulin being a solid phase
protein. It will be of interest to see what subsequent clinical
studies reveal with regard to the post-transplant course of
this genetic mutation.
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Fig. 5 Development of thrombotic microangiopathy with loss of
normal complement regulatory factor function. Loss of alternative
complement pathway regulation caused by loss of function of factors
H and I, membrane co-factor protein or thrombomodulin results in
complement activation directed against endothelial cells. a Mutated
complement factor H cannot bind to cell surface C3b to stop
alternative complement pathway attack. b Mutated complement factor
I cannot cleave C3b. c Mutated membrane co-factor protein cannot
work with factor I to degrade C3b. d Mutated thrombomodulin cannot
bind C3b and accelerate factor I-medicated inactivation of C3b. It
cannot activate thrombin activatable fibrinolysis inhibitor (TAFI),
which inactivates anaphylatoxins C3a and C5a. It also cannot bind
thrombin. With the loss of these regulatory functions of each of these
factors C3b is not inactivated and progression of the complement
cascade ensues. C3b then binds with Bb and then further C3b bind to
this complex, which forms C5 convertase. This cleaves C5 to C5b and
the resulting cascade results in formation of the membrane attack
complex (MAC). C3a and C5a act as anaphylatoxins, which attract
neutrophils to the cells under complement attack. Activating mutations
of factor B and C3b also result in progression of the complement
pathway. The result of any of these mutations is endothelial cell
damage, causing exposure of the subendothelial matrix. This results in
a prothrombotic state with fibrin deposition and release of von
Willebrand factor, which attracts platelets to the site. Platelets will
aggregate. The result is a full complement attack and thrombus
formation. Partial or complete vessel occlusion will result. This will
produce platelet consumption and red cell damage and TMA is the
result
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Thrombotic thrombocytopaenic purpura (TTP) was first
described in 1924 [33]. It is more common in female
subjects between the ages of 10 and 39 years. The highest
incidence is seen in the fourth decade. The annual incidence
is 3.7 cases per 1,000,000 [7]. Clinically, it presents as a
pentad of symptoms: microangiopathic haemolytic anae-
mia, thrombocytopaenia, neurological symptoms, renal
damage and fever. It used to be a diagnosis of exclusion;
however, there is now an ADAMTS13 activity assay that
clinches the diagnosis [33]. Plasma exchange was shown to
improve symptoms and is now standard treatment for TTP
[2]. It took 20 years before the reason why plasma
exchange is a useful treatment in TTP was understood
[34]. In 1982, it was noted that TTP patients had ultra-large
multimers of von Willebrand factor circulating in their
blood during periods of remission; thus, it was hypoth-
esised that, as these were not seen in healthy people, that
TTP patients lack a protease that normally cleaves these
ultra-large multimers [33]
Thrombotic thrombocytopaenic purpura is now known to
be a disorder of von Willebrand factor (vWF) regulation [5].
vWF is a glycoprotein produced by endothelial cells that
regulates platelet aggregation and adhesion. When vascular
injury occurs, vWF is released from endothelial cells as ultra-
large multimers (UL-vWF). Some of these stay associated
with the endothelial cell surface providing platelet-binding
sites. They may bind other blood components too, e.g.
leukocytes. Platelet binding to UL-vWF is regulated by the
metalloprotease ADAMTS13 (a-disintegrin-like and metal-
loprotease and thrombospondin repeats). It is a deficiency of
ADAMTS 13 that accounts for the majority of patients with
congenital TTP. The majority of acquired cases occur due to
antibody formation against this molecule [33].
Banno et al. [35] has developed an ADAMTS13
knockout mouse on a pure genetic background SV129.
These mice do not normally develop TMA, but do show a
UL-vWF multimers pattern similar to that seen in TTP.
However, when challenged with platelet and endothelial
agonists, they develop severe thrombocytopaenia. This
suggests that ADAMTS13 deficiency alone is not enough
to cause TMA. A further environmental or genetic hit is
required to develop TTP.
Infection-associated HUS
Diarrhoea-associated HUS
This is the most common cause of HUS [10]. It is
predominantly a disease of childhood, but can also affect
adults, particularly the elderly. Children present with a
history of diarrhoea, which is often bloody in nature. Two
to five days later they present with pallor, weakness and
oligo-anuria. There are approximately 100 cases per year in
the UK [36]. It is fatal in 3–5% of cases. Two-thirds of
diarrhoea-associated HUS (D + HUS) cases require dialysis
therapy in the acute phase [10]. The diarrhoeal illness is
most commonly caused by E. coli O157:H7, although there
are many other serotypes of E. coli that can also cause
HUS. Each of these serotypes produces Shiga toxin (stx),
which is thought to produce HUS. Other bacteria can also
cause HUS, e.g. Shigella, Campylobacter. Interestingly,
only 10–15% of children who are infected with enter-
ohaemorrhagic E. coli develop HUS. It is not clear why
these children are susceptible. However, it has been
hypothesised that they may have an underlying genetic
pre-disposition or some other environmental factor that puts
them more at risk. The renal pathogenesis of D + HUS is
not yet fully understood.
At the cellular level the target from Shiga toxin (stx) is
Gb3 [37]. This glycosphingolipid receptor is found on
human endothelial cells, podocytes and tubular cells. It is
unclear which cell is the main target for stx binding to
cause HUS. The glomerular endothelial cell has been the
main focus of study to date. Podocytes and human proximal
tubule cells are also sensitive to stx cytotoxicity.
There are species differences in Gb3 expression [37].
Mice have Gb3 on their tubular cells, but lack Gb3 in their
glomeruli (both endothelial cells and podocytes). This has
limited the ability to use small animal models to study this
disease [29]. Interestingly, Gb3 synthase knockout mice are
fully protected from stx injections suggesting that this is the
only receptor that stx binds and exerts its deleterious effects
[38].
It was previously hypothesised that differences in Gb3
expression between children and adults explained why HUS
was seen more frequently in children, especially younger
children. It was proposed that glomerular Gb3 expression
reduced with age, although total renal Gb3 expression
increased with age. One study looked at stx 1 and 2 staining
of kidneys from fatal adult and paediatric cases of E. coli-
related HUS. They found that infant cases showed stx
binding in the glomeruli and tubules, whilst the geriatric
cases had stx binding in the proximal and distal tubules [39].
However, a later study showed identical patterns of Gb3
expression and stx 1 binding in both adult and paediatric
kidneys, both at glomerular and tubular levels [40]. This
study did only look at stx 1 binding and it is known that stx2
is linked with more severe disease and produces HUS [41].
Older studies looked specifically at Stx2.
Animal models have been created to investigate this
disease process. Greyhounds [42] fed raw meat containing
E. coli developed bloody diarrhoea, skin ulcers and renal
failure. Pathologically, theys h o w e dg l o m e r u l a rT M A .
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stx (1 or 2) injections including glomerular TMA. Large
animal models are expensive and impractical to study and
so attention turned to smaller animal models where
transgenic technology is also available [29]. Rodents (mice
and rats) develop tubular disease with no glomerular effects
in response to stx (oral, IV or IP administration). This is
thought to relate to differences in Gb3 receptor expression
among species. Cows are the reservoir of infection with E.
coli O157. They are asymptomatic carriers and this may aid
the spread of E. coli O157. Their Gb3 expression also
varies from that of humans. Cattle kidneys express Gb3 in
their tubules and collecting ducts, but not in their glomeruli.
This may explain why they do not get glomerular micro-
angiopathy, but a complete explanation of why this occurs
is lacking [44].
A mouse model was created in 2006 that developed some
features of HUS [45]. This model was given stx2 and
lipopolysaccharide (LPS). Mice developed thrombocytopae-
nia, haemolytic anaemia and renal failure. Pathologically,
they still showed evidence of tubular disease, but did show
glomerular fibrin thrombi. It is unclear how the glomerular
effects were produced or whether they followed the primary
tubular damage. Further study is required to help understand
the pathogenesis of D + HUS and TMA.
Streptococcal pneumoniae
Streptococcal pneumoniae-related HUS follows invasive
pneumococcal disease and is linked to having a high bacterial
load. It accounts for 5% of childhood cases of HUS [46]. The
incidence of HUS following pneumococcal infection is
estimated to be 0.4–0.6%. Children under 2 years are most
commonly affected. HUS usually develops 3–13 days after
infection starts. It is associated with a longer period of oligo-
anuria and acute dialysis period than stx HUS. Ten percent of
patients progress to end-stage renal failure and there is 12%
mortality. The highest mortality is related to Streptococcal
pneumoniae meningitis complicated by HUS.
Streptococcal pneumoniae-related HUS is caused by
exposure of the Thomsen–Friedenreich (TF) crypt antigen.
This antigen is found on the surface of erythrocytes,
platelets and glomerular endothelial cells, but is normally
masked by neuraminic acid. All serotypes of S. pneumoniae
produced neuraminidase, which cleaves the n-acetyl neu-
raminic acid from the cell surface and exposes the TF
antigen. The host then produces IgM antibodies, which
bind to the TF antigen. This initiates an immune response
that culminates in the development of HUS with red cells,
platelets and glomerular endothelial cell damage. The TF
antigen can also be found on hepatocytes and this explains
why some patients can develop hepatic dysfunction.
Vascular endothelial growth factor
Recently, it has been shown that the glomerular podocyte
might be important in the pathogenesis of HUS through
vascular endothelial growth factor A (VEGF-A).
Vascular endothelial growth factor is the most important
endothelial growth factor and is vital in maintaining healthy,
normallyfunctioning endothelial cells[47]. In the kidney it is
the podocyte that produces VEGF. VEGF is a complex
protein that is present in various spice variants. Recently,
there has been much interest in this growth factor. In adults,
monoclonal antibodies against VEGF-A (bevacizumab) have
been used in some cancer therapy regimens, as VEGF is
found to be unregulated in many human tumours [48]. Some
of these adults develop renal side effects whilst receiving this
treatment. Initially, proteinuria and hypertension were seen,
but some patients developed glomerular TMA and acute
renal insufficiency. This sparked interest in investigating this
further using VEGF-A transgenic mice models. Whole-body
VEGF-A null mice are embryonically lethal [47]. Homozy-
gous podocyte-specific VEGF-A null mice [49]w h oh a d
VEGF knocked out early in development developed
grossly abnormal glomeruli whose endothelial cells were
immature. Heterozygous podocyte-specific VEGF-A mice
developed renal lesions like those seen in pre-eclampsia
(endotheliosis and bloodless glomeruli). This progressed
to nephrotic syndrome and then renal failure. Thus, VEGF
is essential for the development of normal glomeruli, but
did not explain why the cancer patients developed TMA.
A conditional mouse model in which VEGF-A could be
knocked out in the fully developed podocyte was
therefore developed to selectively knock down VEGF-A
in podocytes using tetracycline-responsive technology
[50]. Fascinatingly, this resulted in a phenotype that
closely resembled HUS with glomerular thrombotic
microangiopathy.
At the cellular level VEGF has been investigated in
the context of Shiga-toxin-induced HUS. VEGF-A is
predominantly produced by the podocyte in the kidney
and there is evidence that stx modulates its production
of human, but not murine origin. This is interesting as
mice do not develop a glomerular phenotype when
challenged with stx, unlike man. In vitro it has been
found that human podocytes exposed to stx produce
60% less VEGF-A compared with controls. However,
there is no effect of Shiga toxin on murine podocytes
that do not express the gb3 receptor even when exposing
these cells to 10 times the amount of stx given to human
cells [37].
Vascular endothelial growth factor A is a molecule of
great interest and requires further study to fully understand
its role in other disease models that pathologically exhibit
TMA.
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It is now clear that there are multiple initiators of glomerular
microangiopathy. Our understanding of atypical HUS has
greatly progressed over recent decades, as illustrated by the
plethora of alternative complement regulatory abnormalities
that result in this condition. However, there are still a number
of interesting and fundamental questions to be answered.
1. Why does HUS predominantly affect the kidney and
TTP the brain?
2. Why does HUS mostly affect children, but TTP adults?
3. What is the renal pathogenesis of D + HUS? Does it
have a link to complement or VEGF-A?
4. Why does E. coli O157 lead to HUS in only 10–15% of
children? Is there a genetic component?
5. Could we manipulate the complement system in patients
with atypicalHUS toswitchoff therelentless complement
activation and thus have a new way to treat HUS?
Although the endothelial cell is a major site of pathological
damage there is now exciting evidence that the podocyte
may play a role in microangiopathy through modulation of
VEGF-A. It will be of interest to see whether a unifying
pathological mechanism can be found for typical and
atypical HUS in years to come.
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Multiple choice questions
Answers appear following the reference list.
1. A major cellular receptor in human Shiga toxin HUS is
called
a) crry
b) Gb3
c) CD42
d) MCP
e) Factor I
2. The predominant pathway that is affected by atypical
HUS is the
a) VEGF-A pathway
b) Lectin complement pathway
c) Alternative complement pathway
d) Classical complement pathway
e) Coagulation pathway
3. Which of the following are solid phase complement
components?
a) Factor H
b) Factor I
c) MCP
d) C3
e) C4
4. After renal transplantation, in which of the following is
there least likely to be a recurrence of HUS in the
transplanted kidney
a) Factor H mutations
b) Factor I mutations
c) C3 mutations
d) MCP mutations
e) Thrombomodulin mutations
5. The cause of pneumococcal-induced HUS is thought to
be
a) Alterations in podocyte-derived VEGF-A
b) Abnormalities in the classical complement pathway
c) Thromboxane hyper-stimulation
d) Exposure of neuraminidase on the cell surfaces
e) Production of neuraminidase by the bacteria expos-
ing the TF antigen
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